Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab Pegol Re-treatment in Psoriasis
NCT00329303Phase 2Completed
- Sponsor
- UCB
- Start
- Apr 2006
- Primary completion
- May 2007
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of certolizumab pegol in plaque psoriasis (2 arms), sponsored by UCB. Primary endpoint: Difference in Psoriasis Activity and Severity Index (PASI) Scores Between Week 12 of the First Treatment in Study C87040 and Week 12 of Re-treatment in This Study. Started Apr 2006; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00329303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00329303.